Literature DB >> 22328314

Type I error rate control in adaptive designs for confirmatory clinical trials with treatment selection at interim.

Martin Posch1, Willi Maurer, Frank Bretz.   

Abstract

Interest in confirmatory adaptive combined phase II/III studies with treatment selection has increased in the past few years. These studies start comparing several treatments with a control. One (or more) treatment(s) is then selected after the first stage based on the available information at an interim analysis, including interim data from the ongoing trial, external information and expert knowledge. Recruitment continues, but now only for the selected treatment(s) and the control, possibly in combination with a sample size reassessment. The final analysis of the selected treatment(s) includes the patients from both stages and is performed such that the overall Type I error rate is strictly controlled, thus providing confirmatory evidence of efficacy at the final analysis. In this paper we describe two approaches to control the Type I error rate in adaptive designs with sample size reassessment and/or treatment selection. The first method adjusts the critical value using a simulation-based approach, which incorporates the number of patients at an interim analysis, the true response rates, the treatment selection rule, etc. We discuss the underlying assumptions of simulation-based procedures and give several examples where the Type I error rate is not controlled if some of the assumptions are violated. The second method is an adaptive Bonferroni-Holm test procedure based on conditional error rates of the individual treatment-control comparisons. We show that this procedure controls the Type I error rate, even if a deviation from a pre-planned adaptation rule or the time point of such a decision is necessary.
Copyright © 2010 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 22328314     DOI: 10.1002/pst.413

Source DB:  PubMed          Journal:  Pharm Stat        ISSN: 1539-1604            Impact factor:   1.894


  9 in total

1.  Two-stage adaptive enrichment design for testing an active factor.

Authors:  A Adam Ding; Samuel S Wu; Natalie E Dean; Rachel S Zahigian
Journal:  J Biopharm Stat       Date:  2019-05-28       Impact factor: 1.051

Review 2.  Adaptive trial designs for spinal cord injury clinical trials directed to the central nervous system.

Authors:  James D Guest; John D Steeves; M J Mulcahey; Linda A T Jones; Frank Rockhold; Rϋediger Rupp; John L K Kramer; Steven Kirshblum; Andrew Blight; Daniel Lammertse
Journal:  Spinal Cord       Date:  2020-09-16       Impact factor: 2.772

3.  Twenty-five years of confirmatory adaptive designs: opportunities and pitfalls.

Authors:  Peter Bauer; Frank Bretz; Vladimir Dragalin; Franz König; Gernot Wassmer
Journal:  Stat Med       Date:  2015-03-16       Impact factor: 2.373

4.  Contemporary strategies to improve clinical trial design for critical care research: insights from the First Critical Care Clinical Trialists Workshop.

Authors:  Michael O Harhay; Jonathan D Casey; Marina Clement; Sean P Collins; Étienne Gayat; Michelle Ng Gong; Samir Jaber; Pierre-François Laterre; John C Marshall; Michael A Matthay; Rhonda E Monroe; Todd W Rice; Eileen Rubin; Wesley H Self; Alexandre Mebazaa
Journal:  Intensive Care Med       Date:  2020-02-18       Impact factor: 17.440

5.  Adaptive graph-based multiple testing procedures.

Authors:  Florian Klinglmueller; Martin Posch; Franz Koenig
Journal:  Pharm Stat       Date:  2014-10-16       Impact factor: 1.894

6.  Maximum type 1 error rate inflation in multiarmed clinical trials with adaptive interim sample size modifications.

Authors:  Alexandra C Graf; Peter Bauer; Ekkehard Glimm; Franz Koenig
Journal:  Biom J       Date:  2014-04-22       Impact factor: 2.207

7.  Flexible selection of a single treatment incorporating short-term endpoint information in a phase II/III clinical trial.

Authors:  Nigel Stallard; Cornelia Ursula Kunz; Susan Todd; Nicholas Parsons; Tim Friede
Journal:  Stat Med       Date:  2015-06-26       Impact factor: 2.373

8.  Adaptive designs in clinical trials: why use them, and how to run and report them.

Authors:  Philip Pallmann; Alun W Bedding; Babak Choodari-Oskooei; Munyaradzi Dimairo; Laura Flight; Lisa V Hampson; Jane Holmes; Adrian P Mander; Lang'o Odondi; Matthew R Sydes; Sofía S Villar; James M S Wason; Christopher J Weir; Graham M Wheeler; Christina Yap; Thomas Jaki
Journal:  BMC Med       Date:  2018-02-28       Impact factor: 8.775

9.  Adaptive designs in clinical trials: from scientific advice to marketing authorisation to the European Medicine Agency.

Authors:  Olivier Collignon; Franz Koenig; Armin Koch; Robert James Hemmings; Frank Pétavy; Agnès Saint-Raymond; Marisa Papaluca-Amati; Martin Posch
Journal:  Trials       Date:  2018-11-20       Impact factor: 2.279

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.